famotidine has been researched along with Obesity in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomez, P | 1 |
| Hallberg, L | 1 |
| Greeley, GH | 1 |
1 other study available for famotidine and Obesity
| Article | Year |
|---|---|
Carboxypeptidase E (CPE) deficiency in mice with the fat mutation have reduced stomach function.
Topics: Animals; Carboxypeptidase H; Carboxypeptidases; Famotidine; Gastric Acid; Gastric Mucosa; Gastrins; | 1999 |